Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$34.6m

Fortress Biotech Future Growth

Future criteria checks 1/6

Fortress Biotech's earnings are forecast to decline at 19.3% per annum while its annual revenue is expected to grow at 14.1% per year. EPS is expected to grow by 12.5% per annum.

Key information

-19.3%

Earnings growth rate

12.5%

EPS growth rate

Biotechs earnings growth20.7%
Revenue growth rate14.1%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Apr 2024

Recent future growth updates

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Jan 11
Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Sep 28
Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Jun 04
Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

Mar 04
Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Feb 06
When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Jan 11
Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15
Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19
Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

Earnings and Revenue Growth Forecasts

NasdaqCM:FBIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026137-112N/AN/A2
12/31/2025110-95N/AN/A3
12/31/202471-98N/AN/A3
12/31/202385-69-136-128N/A
9/30/202362-78-150-141N/A
6/30/202363-96-176-168N/A
3/31/202364-92-182-176N/A
12/31/202276-95-202-179N/A
9/30/202278-97-196-170N/A
6/30/202282-93-181-149N/A
3/31/202281-74-179-142N/A
12/31/202169-65-133-117N/A
9/30/202164-38-113-98N/A
6/30/202153-33-110-101N/A
3/31/202144-43-89-83N/A
12/31/202046-47-91-84N/A
9/30/202043-57-99-88N/A
6/30/202043-54-92-81N/A
3/31/202043-54-102-92N/A
12/31/201937-40-104-95N/A
9/30/201934-45-98-92N/A
6/30/201930-51-106-101N/A
3/31/201927-53-105-96N/A
12/31/201827-73-108-99N/A
9/30/2018-107-61-107-98N/A
6/30/2018-65-69-105-98N/A
3/31/2018-22-72-102-98N/A
12/31/201717-65-85-81N/A
9/30/2017155-74N/A-78N/A
6/30/2017109-60N/A-62N/A
3/31/201761-55N/A-46N/A
12/31/201616-55N/A-46N/A
9/30/20164-50N/A-35N/A
6/30/20163-55N/A-31N/A
3/31/20161-49N/A-30N/A
12/31/20151-48N/A-20N/A
9/30/20151-40N/A-17N/A
6/30/20151-27N/A-14N/A
3/31/20151-25N/A-12N/A
12/31/2014N/A-20N/A-16N/A
9/30/2014N/A-26N/A-20N/A
6/30/2014N/A-30N/A-24N/A
3/31/2014N/A-36N/A-28N/A
12/31/2013N/A-37N/A-30N/A
9/30/2013N/A-36N/A-30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FBIO's revenue (14.1% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: FBIO's revenue (14.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.